ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-ADAM9/Exatecan Antibody-drug Conjugate MGC028

Its studies are led by MacroGenics.

Furthest: phase 1, since Dec 4, 20241 company-led study, 1 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MacroGenics11 open or runningphase 1since Dec 4, 2024Dec 4, 2024Nov 2026phase 1 · NCT06723236

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 4, 2024First study: phase 1 study in CholangiocarcinomaFirst studyNCT06723236 · 124 planned · United States

Ahead

  1. Nov 2026Primary completion: phase 1 study in CholangiocarcinomaNCT06723236

TargetBeta

ADAM9 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) a disintegrin and metalloproteinase domain 9 (ADAM9), site-specifically ”NCIt, by rule

Other programs on ADAM9

ProgramCompanyFurthest phaseStudies
Anti-ADAM9/Pamirtecan Antibody-drug Conjugate DB-1317ruledualitybio-incphase 11
Anti-ADAM9/Topoisomerase-1 Inhibitor Antibody-drug Conjugate BG-C0979ruleBeOne Medicinesphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06723236Cholangiocarcinoma · United States1RecruitingNov 2026124

How it is read

Names in the registry

  • “MGC028”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.